A COMPARATIVE ANALYSIS OF THE THERAPUTICAL EFFICACY OF L-ARGININE L-GLUTAMATE AND THIOTRIAZOLIN IN THE COMPLEX PHARMACOTHERAPY OF STABLE ISCHEMIC HEART DISEASE

Yakovleva О. О., Semenchuk S. A.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The optimal pharmacotherapy of ischemic heart disease (IHD) has been addressed from the perspective of cardiac hemodynamics improvement that is effective in preventing angina attacks but provide virtually no influence against pathogenetic links of the disease. That is why, the metabolic therapy has rightfully taken its leading place among the treatment plans for cardiovascular disease and has been included in the international guidelines. The purpose of the study was to compare effectiveness of L-arginine L-glutamate and thiotriazolin in the complex pharmacotherapy of stable IHD. In accordance with the objectives of the study, 142 subjects with stable IHD were screened. After the previous randomization and correction of outpatient treatment, patients were assigned three treatment options, depending on which the main clinical groups of the study were formed: the first clinical group consisted of 44 patients who received only optimal IHD therapy, the second group — 50 patients who received LArginine L-glutamate in the complex pharmacotherapy, the third group consisted of 48 patients who received the drug — thiotriazolin in addition to standart treatment regimen. The evaluation of the functional state of the liver in patients with stable IHD in the study groups showed superiority of the L-arginine L-glutamate group to decrease in cytolytic and cholestatic syndromes: reduction of ALT in group 2 was by 48,5 % (p<0,05), while in group 3 – by 31,1 % (p<0,05); the level of AST decreased by 43,1 % (p<0,05) and 28,6 %; the level of GGP decreased in group 2 and 3 by 45,7% (p<0,05) and 29,6% (p<0,05) respectively. The level of TC in patients of the 2nd group decreased by – 30,4 % (p<0,05), while in patients of group 3 - by 20,5 %. The mean TG level decreased by 46,8 % (p<0,05) and 27,1 % respectively. Target levels of LDL-C were achieved in the 1st group in 41 % cases, in the 2nd group – in 61 % of patients and in group 3 – 49 %, (p<0,05). The level of HDL-C in patients of group 2 increased by 25,0 % (p<0,05), while in group 2 - by 11,2 %(p<0,05). The anti-ischemic effect of both metabolic drugs was confirmed with 24-hour ECG monitoring, but did not statistically differ

ischemic heart disease, L-arginine L-glutamate, thiotriozolin, liver.

1. Akın L, Kurtoglu S, Yikilmaz A, Kendirci M, Elmalı F, Mazicioglu M. Fatty liver is a good indicator of subclinical atherosclerosis risk in obese children and adolescents regardless of liver enzyme elevation. Acta Paediatr. 2013;102(3):107-13. DOI: 10.1111/apa.12099
2.  Ampuero J, Gallego-Durán R, Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: metaanalysis. Rev Esp Enferm Dig. 2015;107(1):10-6.
3. Kucukazman M, Ata N, Yavuz B, Dal K, Sen O, Deveci OS, et al. Evaluation of early atherosclerosis markers in patients with nonalcoholic fatty liver disease. European journal of gastroenterology & hepatology. 2013;25(2):147-51. Available from: https://doi.org/10.1097/ meg.0b013e32835a58b1
4. Shukla V, Fatima J, Chaudhary S, Ali M, Mishra I. A Study of Endothelial Dysfunction in Patients of Non-Alcoholic Fatty Liver Disease. Journal of The Association of Physicians of India. 2017;65:18.
5. Tabit CE, Chung WB, Hamburg NM, Vita JA. Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Reviews in Endocrine and Metabolic Disorders. 2010;11(1):61-74. DOI: 10.1007/s11154-010-9134-4
6.  Teague HL, Ahlman MA, Alavi A, Wagner DD, Lichtman AH, Nahrendorf M, et al. Unraveling Vascular Inflammation. Journal of the American College of Cardiology. 2017;70(11):1403-12. DOI: 10.1016/j.jacc.2017.07.750
7.  Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart. 2007;93(8):1001-7. DOI: 10.1136/ hrt.2006.088211
8.  Zeikidze S. Diagnostic value of moderate dilatation of the left ventricle in asymptomic (silent) ischemia. Georgian medical news. 2017;271:66- 70.
9.  Simon TG, Bamira DG, Chung RT, Weiner RB, Corey KE. Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. Obesity. 2017;25(8):1313-6. DOI: 10.1002/oby.21879
10. Pandey A, Omar W, Ayers C, LaMonte M, Klein L, Allen NB, et al. Sex and Race Differences in Lifetime Risk of Heart Failure with Preserved Ejection Fraction and Heart Failure with Reduced Ejection Fraction. Circulation. 2018;137(17):1814-23. Available from: https://doi. org/10.1161/circulationaha.117.031622
11.  Babak OYa, Frolov VM, Kharchenko NV. Glutargin–farmakologicheskoye deystviye i klinicheskoye primeneniye. Kharkov: Elton-2; 2005. 456 s. [in Russiаn].
12. Hlutarhin – instruktsiya dlya klinichnoho zastosuvannya preparatu. Zatverdzheno nakazom Ministerstva okhorony zdorov’ya Ukrayiny № 323 vid 05.06.2015. [in Ukrainian].
13. Xuan C, Tian QW, Li H, Zhang BB, He GW, Lun LM. Levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, and risk of coronary artery disease: A meta-analysis based on 4713 participants. European journal of preventive cardiology. 2016;23(5):502-10.
14.  Lymanets TV, Maslova GS, Skrypnyk IM. The nitric oxide system imbalance role in the development of anthracycline cardiotoxicity in acute leukemia patients with concomitant ischemic heart disease. World of Medicine and Biology. 2016;12(57):035-040.
15. Dogru T, Genc H, Tapan S, Ercin CN, Ors F, Aslan F, et al. Elevated asymmetric dimethylarginine in plasma: an early marker for endothelial dysfunction in non-alcoholic fatty liver disease? Diabetes research and clinical practice. 2012;96(1):47-52.
16.  Lee CW, Li D, Channon KM, Paterson DJ. L-arginine supplementation reduces cardiac noradrenergic neurotransmission in spontaneously hypertensive rats. Journal of molecular and cellular cardiology. 2009;47(1):149-55.
17.  Zhang JX, Wang ZM, Zhang JJ, Zhu LL, Gao XF, Chen SL. Association of glutathione peroxidase-1 (GPx-1) rs1050450 Pro198Leu and Pro197Leu polymorphisms with cardiovascular risk: a meta-analysis of observational studies. J Geriatr Cardiol. 2014;11(2):141-50. DOI: 10.3969/j. issn.1671-5411.2014.02.003
18.  Zhang S, Zhang S, Wang H, Wu W, Ye Y. Arginine methylation dysfunction increased risk of acute coronary syndrome in coronary artery disease population: A case-control study. Medicine (Baltimore). 2017;96(7):e6074. DOI: 10.1097/MD.0000000000006074
19.  Tiotryazolin – instruktsiya dlya klinichnoho zastosuvannya. Zatverdzheno nakazom Ministerstva okhorony zdorov’ya Ukrayiny № 905 vid 15.12.2011. [in Ukrainian].
20. Stavrakis S, Scherlag BJ, Fan Y, Liu Y, Mao J, Varma V, et al. Inhibition of atrial fibrillation by low-level vagus nerve stimulation: the role of the nitric oxide signaling pathway. Journal of Interventional Cardiac Electrophysiology. 2013;36(3):199-208.

«Bulletin of problems biology and medicine» Issue 1 Part 2 (149), 2019 year, 211-215 pages, index UDK 615.036

10.29254/2077-4214-2019-1-2-149-211-215